Cell and Advanced Therapies Supply Chain Management - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511244869

Publication Date:

November 4, 2024

Pages:

127

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Cell and Advanced Therapies Supply Chain Management was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Cell and Advanced Therapies Supply Chain Management was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cell and Advanced Therapies Supply Chain Management was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Cell and Advanced Therapies Supply Chain Management was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Cell and Advanced Therapies Supply Chain Management include Be The Match BioTherapies, Brooks Life Sciences, Clarkston Consulting, Cryoport, Haemonetics, Hypertrust Patient Data Care, Lykan Bioscience, MAK-SYSTEM and MasterControl, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cell and Advanced Therapies Supply Chain Management, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cell and Advanced Therapies Supply Chain Management by region & country, by Type, and by Application.
The Cell and Advanced Therapies Supply Chain Management market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Advanced Therapies Supply Chain Management.
麻豆原创 Segmentation
By Company
Be The Match BioTherapies
Brooks Life Sciences
Clarkston Consulting
Cryoport
Haemonetics
Hypertrust Patient Data Care
Lykan Bioscience
MAK-SYSTEM
MasterControl
SAP
SAVSU Technologies
sedApta Group
Stafa Cellular Therapy
Title21 Health Solutions
TraceLink
TrakCel
Vineti
Segment by Type:
Cloud
On-premises
Segment by Application
Biobank
Cell Therapy Lab
Hospital
Research Institute
Commercial Organization
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cell and Advanced Therapies Supply Chain Management manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cell and Advanced Therapies Supply Chain Management in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cell and Advanced Therapies Supply Chain Management in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Cell and Advanced Therapies Supply Chain Management Product Introduction
1.2 Global Cell and Advanced Therapies Supply Chain Management 麻豆原创 Size Forecast
1.3 Cell and Advanced Therapies Supply Chain Management 麻豆原创 Trends & Drivers
1.3.1 Cell and Advanced Therapies Supply Chain Management Industry Trends
1.3.2 Cell and Advanced Therapies Supply Chain Management 麻豆原创 Drivers & Opportunity
1.3.3 Cell and Advanced Therapies Supply Chain Management 麻豆原创 Challenges
1.3.4 Cell and Advanced Therapies Supply Chain Management 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cell and Advanced Therapies Supply Chain Management Players Revenue Ranking (2023)
2.2 Global Cell and Advanced Therapies Supply Chain Management Revenue by Company (2019-2024)
2.3 Key Companies Cell and Advanced Therapies Supply Chain Management Manufacturing Base Distribution and Headquarters
2.4 Key Companies Cell and Advanced Therapies Supply Chain Management Product Offered
2.5 Key Companies Time to Begin Mass Production of Cell and Advanced Therapies Supply Chain Management
2.6 Cell and Advanced Therapies Supply Chain Management 麻豆原创 Competitive Analysis
2.6.1 Cell and Advanced Therapies Supply Chain Management 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Cell and Advanced Therapies Supply Chain Management Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Advanced Therapies Supply Chain Management as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cloud
3.1.2 On-premises
3.2 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Type
3.2.1 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cell and Advanced Therapies Supply Chain Management Sales Value, by Type (2019-2030)
3.2.3 Global Cell and Advanced Therapies Supply Chain Management Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Biobank
4.1.2 Cell Therapy Lab
4.1.3 Hospital
4.1.4 Research Institute
4.1.5 Commercial Organization
4.2 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Application
4.2.1 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cell and Advanced Therapies Supply Chain Management Sales Value, by Application (2019-2030)
4.2.3 Global Cell and Advanced Therapies Supply Chain Management Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Region
5.1.1 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Region (2019-2024)
5.1.3 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Region (2025-2030)
5.1.4 Global Cell and Advanced Therapies Supply Chain Management Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
5.2.2 North America Cell and Advanced Therapies Supply Chain Management Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
5.3.2 Europe Cell and Advanced Therapies Supply Chain Management Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
5.4.2 Asia Pacific Cell and Advanced Therapies Supply Chain Management Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
5.5.2 South America Cell and Advanced Therapies Supply Chain Management Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
5.6.2 Middle East & Africa Cell and Advanced Therapies Supply Chain Management Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cell and Advanced Therapies Supply Chain Management Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cell and Advanced Therapies Supply Chain Management Sales Value
6.3 United States
6.3.1 United States Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
6.3.2 United States Cell and Advanced Therapies Supply Chain Management Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cell and Advanced Therapies Supply Chain Management Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
6.4.2 Europe Cell and Advanced Therapies Supply Chain Management Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cell and Advanced Therapies Supply Chain Management Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
6.5.2 China Cell and Advanced Therapies Supply Chain Management Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cell and Advanced Therapies Supply Chain Management Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
6.6.2 Japan Cell and Advanced Therapies Supply Chain Management Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cell and Advanced Therapies Supply Chain Management Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
6.7.2 South Korea Cell and Advanced Therapies Supply Chain Management Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cell and Advanced Therapies Supply Chain Management Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
6.8.2 Southeast Asia Cell and Advanced Therapies Supply Chain Management Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cell and Advanced Therapies Supply Chain Management Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cell and Advanced Therapies Supply Chain Management Sales Value, 2019-2030
6.9.2 India Cell and Advanced Therapies Supply Chain Management Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cell and Advanced Therapies Supply Chain Management Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Be The Match BioTherapies
7.1.1 Be The Match BioTherapies Profile
7.1.2 Be The Match BioTherapies Main Business
7.1.3 Be The Match BioTherapies Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.1.4 Be The Match BioTherapies Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.1.5 Be The Match BioTherapies Recent Developments
7.2 Brooks Life Sciences
7.2.1 Brooks Life Sciences Profile
7.2.2 Brooks Life Sciences Main Business
7.2.3 Brooks Life Sciences Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.2.4 Brooks Life Sciences Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.2.5 Brooks Life Sciences Recent Developments
7.3 Clarkston Consulting
7.3.1 Clarkston Consulting Profile
7.3.2 Clarkston Consulting Main Business
7.3.3 Clarkston Consulting Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.3.4 Clarkston Consulting Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.3.5 Cryoport Recent Developments
7.4 Cryoport
7.4.1 Cryoport Profile
7.4.2 Cryoport Main Business
7.4.3 Cryoport Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.4.4 Cryoport Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.4.5 Cryoport Recent Developments
7.5 Haemonetics
7.5.1 Haemonetics Profile
7.5.2 Haemonetics Main Business
7.5.3 Haemonetics Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.5.4 Haemonetics Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.5.5 Haemonetics Recent Developments
7.6 Hypertrust Patient Data Care
7.6.1 Hypertrust Patient Data Care Profile
7.6.2 Hypertrust Patient Data Care Main Business
7.6.3 Hypertrust Patient Data Care Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.6.4 Hypertrust Patient Data Care Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.6.5 Hypertrust Patient Data Care Recent Developments
7.7 Lykan Bioscience
7.7.1 Lykan Bioscience Profile
7.7.2 Lykan Bioscience Main Business
7.7.3 Lykan Bioscience Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.7.4 Lykan Bioscience Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.7.5 Lykan Bioscience Recent Developments
7.8 MAK-SYSTEM
7.8.1 MAK-SYSTEM Profile
7.8.2 MAK-SYSTEM Main Business
7.8.3 MAK-SYSTEM Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.8.4 MAK-SYSTEM Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.8.5 MAK-SYSTEM Recent Developments
7.9 MasterControl
7.9.1 MasterControl Profile
7.9.2 MasterControl Main Business
7.9.3 MasterControl Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.9.4 MasterControl Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.9.5 MasterControl Recent Developments
7.10 SAP
7.10.1 SAP Profile
7.10.2 SAP Main Business
7.10.3 SAP Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.10.4 SAP Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.10.5 SAP Recent Developments
7.11 SAVSU Technologies
7.11.1 SAVSU Technologies Profile
7.11.2 SAVSU Technologies Main Business
7.11.3 SAVSU Technologies Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.11.4 SAVSU Technologies Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.11.5 SAVSU Technologies Recent Developments
7.12 sedApta Group
7.12.1 sedApta Group Profile
7.12.2 sedApta Group Main Business
7.12.3 sedApta Group Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.12.4 sedApta Group Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.12.5 sedApta Group Recent Developments
7.13 Stafa Cellular Therapy
7.13.1 Stafa Cellular Therapy Profile
7.13.2 Stafa Cellular Therapy Main Business
7.13.3 Stafa Cellular Therapy Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.13.4 Stafa Cellular Therapy Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.13.5 Stafa Cellular Therapy Recent Developments
7.14 Title21 Health Solutions
7.14.1 Title21 Health Solutions Profile
7.14.2 Title21 Health Solutions Main Business
7.14.3 Title21 Health Solutions Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.14.4 Title21 Health Solutions Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.14.5 Title21 Health Solutions Recent Developments
7.15 TraceLink
7.15.1 TraceLink Profile
7.15.2 TraceLink Main Business
7.15.3 TraceLink Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.15.4 TraceLink Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.15.5 TraceLink Recent Developments
7.16 TrakCel
7.16.1 TrakCel Profile
7.16.2 TrakCel Main Business
7.16.3 TrakCel Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.16.4 TrakCel Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.16.5 TrakCel Recent Developments
7.17 Vineti
7.17.1 Vineti Profile
7.17.2 Vineti Main Business
7.17.3 Vineti Cell and Advanced Therapies Supply Chain Management Products, Services and Solutions
7.17.4 Vineti Cell and Advanced Therapies Supply Chain Management Revenue (US$ Million) & (2019-2024)
7.17.5 Vineti Recent Developments
8 Industry Chain Analysis
8.1 Cell and Advanced Therapies Supply Chain Management Industrial Chain
8.2 Cell and Advanced Therapies Supply Chain Management Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cell and Advanced Therapies Supply Chain Management Sales Model
8.5.2 Sales Channel
8.5.3 Cell and Advanced Therapies Supply Chain Management Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Be The Match BioTherapies
Brooks Life Sciences
Clarkston Consulting
Cryoport
Haemonetics
Hypertrust Patient Data Care
Lykan Bioscience
MAK-SYSTEM
MasterControl
SAP
SAVSU Technologies
sedApta Group
Stafa Cellular Therapy
Title21 Health Solutions
TraceLink
TrakCel
Vineti

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.